JULY 2025 • VOLUME 25-10
PHARMACY EDITION

NOVA SCOTIA

PharmacareNEWS

inside

Nova Scotia Formulary Updates

New Exception Status Products

The following new products have been listed with the following criteria, effective **August 1, 2025**.

PRODUCT	STRENGTH	DIN	BENEFIT STATUS	MFR
Uplizna (inebilizumab)	10mg/mL Vial	02543931	E (SF)	AGA

Criteria

Initiation:

- For the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who meet all of the following criteria:
  - Anti-aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive
  - Have had ≥ 1 attack in the prior 12 months or ≥ 2 attacks in the prior 2 years
  - Patients must have an EDSS score of 8 points or less

Renewal:

- The physician should measure and provide EDSS scores every 12 months after the initial authorization to determine if the continuation of inebilizumab reimbursement should occur.

Discontinuation:

- Reimbursement of inebilizumab treatment should be discontinued if the patient's EDSS score is greater than 8 points.

Claim Notes:

- Initial and renewal approval: 12 months
- The prescribing of inebilizumab for the treatment of NMOSD should be restricted to neurologists with expertise in treating NMOSD.

New Exception Status Products Continued…

PRODUCT	STRENGTH	DIN	BENEFIT STATUS	MFR
Uplizna (inebilizumab)	10mg/mL Vial	02543931	E (SF)	AGA
Criteria	• Inebilizumab should not be initiated during a NMOSD relapse episode. • Inebilizumab should not be reimbursed when used in combination with rituximab, satralizumab, eculizumab, or ravulizumab. • Approvals will be a for a maximum of 300 mg at 0 and 2 weeks and 300 mg every 6 months thereafter.			

PRODUCT	STRENGTH	DIN	BENEFIT STATUS	MFR
Lysodren (mitotane)	500mg Tab	00463221	C, E (SF)	MDU
Criteria	• For the treatment of advanced adrenocortical cancer. • For the treatment of metastatic adrenocortical cancer in combination with doxorubicin, etoposide, cisplatin.			

Criteria Update

The following new indication has been added to existing criteria effective **August 1, 2025**.

PRODUCT	STRENGTH	DIN	BENEFIT STATUS	MFR
Alecensaro (alectinib)	150mg Cap	02458136	E (SFC)	HLR
Criteria	**Early-Stage Non-Small Cell Lung Cancer** • For the adjuvant treatment of adult patients with resected ALK-positive non-small cell lung cancer (NSCLC) tumors that are ≥ 4cm and/or are locoregional lymph node positive with no distant spread of disease. **Clinical Notes:** • Treatment should continue until disease recurrence, unacceptable toxicity, or to a maximum of two years. • Patients will be eligible for ALK inhibitors in the advanced setting if disease recurrence occurs at least 6 months after the last dose of adjuvant alectinib. • Patients should have a good performance status.			

New Benefits

Effective **August 1, 2025,** the following products will be added as benefits in the Nova Scotia Formulary. The benefit status within the Pharmacare Programs is indicated and existing criteria applies.

PRODUCT	STRENGTH	DIN	BENEFIT STATUS	MFR
Brukinsa	160mg Tab	02554267	E (SFC)	BGN
FreeStyle Libre 3 Plus Sensor		97798966	E (SF), G	MID
Wezlana	45mg/0.5mL Prefilled Autoinjector	02553317	E (SF)	AGA
Wezlana	90mg/1.0mL Prefilled Autoinjector	02553309	E (SF)	AGA